Fauci lays out HIV research plan

A week after suspending a major HIV vaccine trial set to commence soon, linkurl:Anthony Fauci,;http://www.the-scientist.com/article/display/13734/ head of the National Institute of Allergies and Infectious Diseases (NIAID), has laid out a plan for reshuffling priorities in HIV/AIDS vaccine development in an article appearing in Science tomorrow (July 25), coauthored by a slew of HIV vaccine researchers. "The general trend will be funding a bit more fundamental discovery research," Fauci said,

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
A week after suspending a major HIV vaccine trial set to commence soon, linkurl:Anthony Fauci,;http://www.the-scientist.com/article/display/13734/ head of the National Institute of Allergies and Infectious Diseases (NIAID), has laid out a plan for reshuffling priorities in HIV/AIDS vaccine development in an article appearing in Science tomorrow (July 25), coauthored by a slew of HIV vaccine researchers. "The general trend will be funding a bit more fundamental discovery research," Fauci said, echoing a linkurl:pledge;http://www.the-scientist.com/blog/display/54488/ he made at an NIAID conference back in March. NIAID is still solidifying some future initiatives, Fauci said, such as plans to attract more young investigators to HIV vaccine research by offering more grants for such studies, and to encourage more collaboration between non-human primate researchers and scientists at human clinical centers. The NIAID is also planning a November conference on non-human primate research on HIV vaccines, Fauci said, and in May funded a linkurl:$15.6 million project;http://www.the-scientist.com/blog/display/54655/ to study antibody responses from B cells instead of targeting T cells - the approach taken by previous vaccine efforts. More recently, NIAID announced another linkurl:program;http://www.niaid.nih.gov/ncn/budget/concepts/c-aid0108.htm#01 to fund research into how HIV transmission can be interrupted. The move to basic research "doesn't mean we're going to stop all clinical trials," Fauci explained. Instead, he said, the scientific bar for taking an HIV vaccine candidate into the realm of clinical trials has been raised. "There will be some reduction in spending on clinical trials and clinical networks," said Dennis Burton, a coauthor on the article and an NIH funded HIV vaccine researchers at the Scripps Research Institute, "in part because there are no really good candidates to put into those networks." Fauci said that he decided to linkurl:discontinue;http://www.the-scientist.com/blog/display/54838/ the AIDS vaccine trial, known as PAVE 100, despite its linkurl:support;http://www.the-scientist.com/blog/display/54724/ by the NIH's AIDS Vaccine Research Subcommittee last month, after mulling over the data from the linkurl:failed trial;http://www.the-scientist.com/blog/display/53633/ of a Merck vaccine, and speaking with researchers and other interested parties. "I couldn't see justifying the PAVE 100 trial as it was defined," Fauci said. "You've got to show me it works first." To that end, Fauci said that he would entertain a "leaner, meaner" trial that tested the science behind the PAVE vaccine, and that researchers were already designing such a trial. "Hopefully in a few weeks to a month, we'll have something to look at," he said.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo